Company intelligence / Profile preview

Sapphiros AI Bio

Boston, Massachusetts, United Statessapphiros.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

Sapphiros AI Bio has completed two preclinical animal studies with promising results using its proprietary human-derived cellular product for cartilage regeneration. Additional R&D is ongoing in cardiac repair and other therapeutic targets. Products are currently under development; none have reached clinical trials yet.

Therapeutic areas: CardiovascularRheumatologyNeurology
Modalities: Cell therapies (including off-the-shelf cell therapies)Pluripotent stem cells and differentiated cell types
Industry: Biotech

Beyond the preview

Go deeper on Sapphiros AI Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sapphiros AI Bio.

Explore the full profile